Drug maker Dr Reddy's Laboratories today launched a new inhaler consisting of dose counting device for the first time in the country.
The inhalers are used in the treatment of patients having asthmatic problems and other respiratory complications.
The new metred dose inhaler would patients provide an advance indication so that they could buy another device before it finishes, Dr Reddy's Laboratories said in a filing with the Bombay Stock Exchange (BSE).
The new inhaler changes colour from green to red as its medication finishes, it said.
The device also includes a retractable mouthpiece and a child-lock facility, it further said.
The dose counting inhaler comes with an universal adaptor that can be fitted with available spacers, the filing added.
The inhaler is a new drug delivery device with a single piece having 120 metred doses, the company said.
Dr Reddy's Lab had entered the Rs 629-crore inhaler market in 2008 with the launch of its inhaler which is a combination of a steroid and a long act bronchodilator.
Shares of the company closed at Rs 1,231, up 3.35 per cent from previous close on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
